PMID- 25151214
OWN - NLM
STAT- MEDLINE
DCOM- 20150731
LR  - 20181202
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 92
IP  - 3
DP  - 2014 Dec
TI  - Alternative dosing schedules for sunitinib as a treatment of patients with 
      metastatic renal cell carcinoma.
PG  - 208-17
LID - S1040-8428(14)00132-2 [pii]
LID - 10.1016/j.critrevonc.2014.07.006 [doi]
AB  - Sunitinib malate (Sutent; Pfizer, Inc., New York, NY) is an oral multitargeted 
      tyrosine kinase inhibitor that inhibits VEGF receptors (VEGFR-1, VEGFR-2, and 
      VEGFR-3) among a family of kinase targets and have a central role in first-line 
      treatment of metastatic renal cell carcinoma (mRCC). The approved schedule for 
      sunitinib is 50mg/day oid in the so called "4 weeks on and two weeks off" (4/2 
      schedule). Since treatment with sunitinib can be maintained for years, adequate 
      treatment of adverse events (AEs) and care for quality of life is essential. For 
      this reason, several alternative schedules have been proposed in order to 
      personalize sunitinib administration and reduce related toxicity. This review 
      discusses the efficacy and tolerability of alternative regimens to the standard 
      4/2 schedule that have been investigated in RCC patients including schedule of 
      50mg/day 2-weeks on/1-week off, continuous schedule of 37.5mg daily and the "Stop 
      and Go strategy".
CI  - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Guida, Fancesco Maria
AU  - Guida FM
AD  - Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, 
      Italy.
FAU - Santoni, Matteo
AU  - Santoni M
AD  - Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche 
      Region, via Conca 71, 60126 Ancona, Italy.
FAU - Conti, Alessandro
AU  - Conti A
AD  - Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche 
      Region, via Conca 71, 60126 Ancona, Italy.
FAU - Burattini, Luciano
AU  - Burattini L
AD  - Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche 
      Region, via Conca 71, 60126 Ancona, Italy.
FAU - Savini, Agnese
AU  - Savini A
AD  - Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche 
      Region, via Conca 71, 60126 Ancona, Italy.
FAU - Zeppola, Tea
AU  - Zeppola T
AD  - Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, 
      Italy.
FAU - Caricato, Marco
AU  - Caricato M
AD  - Department of General Surgery, Campus Bio-Medico University of Rome, Rome, Italy.
FAU - Cascinu, Stefano
AU  - Cascinu S
AD  - Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche 
      Region, via Conca 71, 60126 Ancona, Italy.
FAU - Tonini, Giuseppe
AU  - Tonini G
AD  - Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, 
      Italy.
FAU - Santini, Daniele
AU  - Santini D
AD  - Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, 
      Italy. Electronic address: d.santini@unicampus.it.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20140806
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Angiogenesis Inhibitors/*administration & dosage
MH  - Antineoplastic Agents/*administration & dosage
MH  - Carcinoma, Renal Cell/*drug therapy/*pathology
MH  - Drug Administration Schedule
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Kidney Neoplasms/*drug therapy/*pathology
MH  - Neoplasm Metastasis
MH  - Pyrroles/*administration & dosage
MH  - Sunitinib
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alternative schedule
OT  - Metastatic renal cell carcinoma
OT  - Sunitinib
OT  - Two weeks on/one week off.
EDAT- 2014/08/26 06:00
MHDA- 2015/08/01 06:00
CRDT- 2014/08/25 06:00
PHST- 2014/02/12 00:00 [received]
PHST- 2014/06/26 00:00 [revised]
PHST- 2014/07/23 00:00 [accepted]
PHST- 2014/08/25 06:00 [entrez]
PHST- 2014/08/26 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
AID - S1040-8428(14)00132-2 [pii]
AID - 10.1016/j.critrevonc.2014.07.006 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2014 Dec;92(3):208-17. doi: 
      10.1016/j.critrevonc.2014.07.006. Epub 2014 Aug 6.